Guidance Uncertainty Resolved At Albany Molecular Research, 2015 Margin ... - Benzinga

Guidance Uncertainty Resolved At Albany Molecular Research, 2015 Margin ...
Benzinga
In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating and $19.00 price target on Albany Molecular Research (NASDAQ: AMRI). In the report, Morgan Stanley noted, "With uncertainty about 2015 guidance ...